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Abstract
Purpose: Radiation dermatitis is a common side effect of radiation therapy (RT). In severe cases,
RT must be interrupted until the skin heals, which can compromise treatment. The purpose of the
study was to compare an anionic polar phospholipid (APP)-based cream and an aloe vera-based gel
to determine their effectiveness in preventing and treating radiation dermatitis.
Patients and methods: Forty-five pediatric patients (median age, 11 years) with various
diagnoses who received at least 23.4 Gy participated. APP cream and aloe vera gel were
symmetrically applied within the irradiated field after each treatment. Three measures were
collected before, during and after completion of treatment: subject's skin comfort, dermatologic
assessment, and common toxicity criteria (CTC).
Results: Significant differences in specific variables favoring APP cream use were noted in some
patients including skin comfort variables, dry (p = 0.002), soft (p = 0.057), feels good (p = 0.002),
rough (p = 0.065), smooth (p = 0.012) and dermatologic variables, dryness (p = 0.013), erythema
(p = 0.002) and peely (p = 0.008). Grouped CTC scores were supportive of APP cream (p = 0.004).
In comparing the first and last assessments, two dermatologic variables, dryness (p = 0.035) and
peely (p = 0.016), favored APP cream.
Conclusion: APP cream is more effective than aloe vera-based gel for prevention and treatment
of radiation dermatitis.
Background
The prevention and treatment of radiation dermatitis is
required for all radiation oncology patients, regardless of
the intensity of therapy. Skin care is an important function
of the radiation oncology nursing staff, and the skin is
routinely evaluated by the attending physician. Reducing
skin toxicity is important, because it allows a patient to
complete a continuous course of RT and minimizes the
intensity of radiochemotherapy interactions that are com-
mon among patients who receive combined modality
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therapy. No product has been identified as the superior
treatment for radiation dermatitis. Therefore, skin reac-
tions remain a common cause of patient discomfort and
cancer treatment delay.
The epidermis (the outer skin) consists of four layers: the
stratum basale (the internal layer), the stratum spinosum,
the stratum granulosum, and the stratum corneum (the
surface layer). The stratum corneum is impermeable, and
its cells, the corneocytes, are considered dead tissue. The
sebaceous glands secrete sebum (oil) onto the impermea-
ble surface of the skin. Sebum is mostly triglyceride in
character and chemistry, and it provides an occlusive oil
film barrier on the surface of the skin to regulate evapora-
tion of water. Strategies aimed at protecting the skin from
desiccation and degradation focus on the lamellar struc-
ture of the stratum cornea and maintenance of the lipid
bilayers, which requires a combination of external and
internal oils and moisture (hydration) [1]. Phospholipids
are key molecules in the formulation of products that
maintain the lamellae, and contemporary skin care tech-
nology has made it possible to mix oil and water to create
products that can be used to keep skin soft, smooth, and
supple [2].
Proactive treatment to prevent radiation dermatitis is
directed at reducing the drying effect of radiation on the
skin and involves instructing patients to avoid irritating
the irradiated region. Dryness due to RT leads to desqua-
mation and loss of the superficial protective layers of the
skin including lipid barriers. Simple moisturizers are
applied in an effort to hydrate the skin and form a barrier
to transcutaneous water loss and topical steroids are
applied to reduce pruritus.
To date, there is no consensus regarding the optimal man-
agement of radiation dermatitis [3-5], and treatment often
follows the management of other dermatoses. There are a
number of reports from prospective controlled clinical
studies for breast cancer patients including phase II and III
trials comparing different agents in the treatment of radi-
ation dermatitis. In one Phase III trial, 194 female patients
receiving breast or chest-wall irradiation were randomized
to receive an aloe vera gel or placebo gel, and 108 female
patients undergoing the same treatment received either
aloe vera gel or no treatment. The investigators concluded
that aloe vera gel did not protect against RT-induced der-
matitis [6]. One study concluded that biafine cream
(water-based emulsion) was useful to avoid delays or
interruptions after chemo-radiotherapy for breast cancer
even though the majority of patients developed Grade 2
radiation dermatitis[7]. Other studies in similar patient
populations have not shown that Biafine and Lipiderm
have a radioprotective effect on the skin [8] nor that
Biafine is better than best supportive care [9]. Agents
incorporating hyaluronic-acid [10], potent topical corti-
costeroids [11], or specific plant extracts (calendula) [12]
have shown promising results in the prevention and treat-
ment of acute dermatitis though suppression of cytokine
responses and inflammation or immune cell modulation.
In another trials, hydrogel or dry dressings [13], and
sucralfate or aqueous creams [14] have been tested on
their ability to reduce the time to healing of moist desqua-
mation after radiotherapy to the head-and-neck, breast, or
anorectal areas.
We used a novel anionic polar phospholipid (APP)-based
skin cream in a side-by-side comparison in individual
patients in the same manner that we routinely perform
prophylactic skin care. The APP cream was previously
evaluated in a double-blind trial for the prevention and
control of dryness, inflammation, and fissures on the feet
of patients with diabetes [15]. Similar agents have been
considered to replenish the tear film phospholipid layer
[16]. The purpose of this study was to compare the effec-
tiveness of the novel APP cream with that of aloe vera gel
in the prevention of radiation dermatitis in children
treated with fractionated external-beam irradiation. Varia-
bles tested included the subjective assessments by the
patient of skin dryness, softness, satisfaction, roughness,
and smoothness and examiner assessment of skin dry-
ness, erythema, and peeling.
Methods
This study was approved by the St. Jude Institutional
Review Board, and informed consent was obtained from
the patient or guardian, as appropriate, before the patient
was enrolled. Study criteria included age older than 3
years and younger than 21, a diagnosis that required exter-
nal-beam irradiation, no prior history of RT at the site to
be evaluated, a prescribed total dose of RT greater than or
equal to 23.4 Gy, no anticipated use of superficial tissue
compensators ("bolus"), no pre-existing dermatologic
condition that would preclude the evaluation of the skin
at the site to be treated (infection, trauma, collagen vascu-
lar disease), no contraindications to the use of the study
treatments or any of their components, and adequate per-
formance status as determined by the ECOG (Eastern
Cooperative Oncology Group) scale (0–3) [17].
Evaluations, tests, and observations
There were three observation measures: (1) the subject
skin comfort assessment, (2) clinical dermatologic assess-
ment, and (3) assessment by the Common Toxicity Crite-
ria (CTC) Version 1.0 of the National Cancer Institute.
These measures were obtained before initiation of RT,
weekly during treatment, and at the time of first follow-up
examination, which typically occurred 4 to 6 weeks after
completion of RT. These measures were also obtained atRadiation Oncology 2007, 2:45 http://www.ro-journal.com/content/2/1/45
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the time of skin care failure. Each patient underwent two
to six evaluations that included all three measures.
The subject skin comfort assessment was completed by
the patient or a parent. The assessment consisted of 15
items (variables), each on a 4-level scale (Figure 1). This
assessment included both positive items (e.g., "soft" and
"feels good") and negative items (e.g., "itch" and "dry").
The dermatologic assessment (Figure 1), which was com-
pleted by the nursing staff, was a similar questionnaire but
consisted of negative items only (e.g., "dryness" and "ery-
thema"). The CTC for adverse events involving the skin
was as follows: grade 1 – none or no change; grade 2 –
scattered macular or papular eruption or erythema that is
asymptomatic; grade 3 – scattered macular or papular
eruption or erythema with pruritis or other associated
symptoms; grade 4-generalized symptomatic macular,
popular, or vesicular eruption; grade 5 – exfoliative der-
matitis or ulcerating dermatitis.
Pretreatment evaluation
Patients underwent fluoroscopic simulation before actual
therapy was initiated. After the simulation, the patient was
evaluated in the radiation oncology clinic by the attend-
ing physician and nursing staff. Study questionnaires were
completed once the anatomic study region (region, site,
and area are used interchangeably) was defined, divided
into two parts, and photographed (Figure 2). The study
focused on patients whose radiation treatment fields
allowed for easy access and examination. Patients who
received craniospinal irradiation or mantle irradiation
had symmetrical irradiation of the region between the
mastoids and the clavicles; these regions were often cho-
sen for ease of study. Patients who received RT to an
extremity, the trunk, or abdomen were included if the
Study Questionnaires Figure 1
Study Questionnaires. The Subject Skin Condition Assessment form (A) and Dermatologic Assessment form (B) are presented.
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homogeneity of radiation dose permitted a well-defined
anatomic region to be evaluated.
Treatment and evaluation during radiation therapy
Patients received at a minimum conventionally fraction-
ated doses of 1.5–1.8 Gy, delivered once a day. The mini-
mum total dose was 23.4 Gy. Each day, after completing
RT, the patient was seen in the radiation oncology clinic
by a nurse who applied the aloe vera gel and the APP skin
cream to the designated study site. The treating radiation
oncologist evaluated the patient once during each interval
of five treatments. At that time, a dermatologic exam was
performed, and study questionnaires were completed.
Each evaluation was designated according to the treat-
ment day (day 5, day 10, day 15, etc.); the patients were
also evaluated on the last day of treatment, which often
did not coincide with a weekly evaluation.
Identification of skin care failure
Skin care failure was identified by one of two means:
Either patients informed the nursing staff that their skin
was dry to the extent that the resultant pruritus was
unbearable, or the nursing staff noticed a transition from
dry to moist desquamation. Dermatologic examination
and subject skin comfort assessment questionnaires were
performed after skin care failure; the next level of skin care
was administered to the site in which that specific product
had failed; and no further data were gathered for the failed
site. Both sites were continually evaluated on a weekly
basis. According to the standards of practice at the time,
follow-up examinations were done 4 to 6 weeks after
completion of RT.
Treatment and evaluation after Radiation Therapy
Patients returned to the radiation oncology clinic 4 to 6
weeks after completion of RT for routine follow-up. Dur-
ing that visit, questionnaires were completed, and photo-
graphs were taken of the treatment site if skin care failure
had not occurred at both sites. The evaluation was similar
to that given during RT.
APP skin cream
The APP skin cream (Ocular Research of Boston (ORB),
Inc, Boston, MA) is a novel oil-in-water emulsion that was
prepared in an FDA-approved facility under cGMP guide-
lines, but it is not commercially available. The active
ingredients of APP cream are triglycerides and phospholi-
pids preserved with benzyl alcohol, methyl paraben, pro-
pyl paraben, and diaxolipinyl urea. It was applied
topically and liberally to the affected area with the bare
hand. Application of the cream was accomplished with
the ventral surface of the fingers using a rotary motion of
the fingers with light pressure to the skin. The cream was
massaged into the skin until the surface of the skin no
longer felt greasy. Inadequate application was noted by
the appearance of a white residual film on the skin.
Aloe vera gel
The aloe vera gel which was commercially available, con-
tained water, aloe vera, D-panthenol, triethanolamine,
carbomer 934P, hyaluronic acid, potassium sorbate, dia-
zolidinyl urea, methylparaben, and propylparaben. The
gel was applied in a manner identical to that described
above for the APP cream.
Statistical considerations
The study was designed as a prospective and randomized
Phase III clinical trial with a planned accrual of 45 eligible
patients. The APP cream and aloe vera gel were symmetri-
cally and adjacently applied to the irradiated sites in indi-
vidual patients; the side treated with cream or gel was
chosen randomly for each patient at the beginning of
treatment, and this status was kept for the entire process
of RT. The primary endpoint is the skin care failure which
included onset of moderate-to-severe dryness, pruritus,
erythema, and dry desquamation. For each individual
patient, the cream is better than gel if gel fails before
cream does; and vice versa. The sample size for the study
Photograph of patient who received mantle irradiation and  outline of symmetric areas for study Figure 2
Photograph of patient who received mantle irradiation and 
outline of symmetric areas for study.
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was calculated to test whether the cream is better than the
gel, or equivalently to test the hypothesis that the propor-
tion of patients for whom the cream is better than gel is
more than 50%. 45 patients were planned for this study to
detect a proportion of 70% (cream better than gel) with a
power of 0.86 and a significance level of 0.05.
At pre-treatment, no statistical test was performed because
the scores of both subject skin comfort and dermatologic
assessments, along with CTC scores, were identical
between cream and gel in all 45 patients. During radiation
therapy we compared the probability that cream is better
than or equal to gel with the probability that gel is better
than or equal to cream using a conditional test with bino-
mial distribution. Longitudinal mixed models were not
considered appropriate for assessment score comparison
during radiation therapy because cream and gel had iden-
tical scores in a number of patients. At follow-up, t-tests
were performed to compare scores of cream and gel.
Statistical analyses were performed using either SAS®
(Cary, North Carolina) or StatExact-5 (Cytel Software
Corporation, Cambridge, Massachusetts). The statisti-
cians were blinded as to knowledge of cream or gel during
the analysis. The significance level was at type I error rate
alpha = 0.05 for all tests. The P-values were not adjusted
for multiple testing.
Results
The trial included 45 pediatric patients whose average age
was 10 years (range, 3–19 years). The average total dose of
radiation was 34.3 Gy (range, 25.2–67 Gy). The most
common diagnoses were Hodgkin disease (n = 16), CNS
tumor (n = 10), pediatric sarcoma (n = 8), and neuroblas-
toma (n = 6). The most common treatment sites were the
thorax, upper thorax, axilla, and craniocervical regions.
One patient with two sites to assess was removed from the
final analysis because they were the lone case with two
sites.
Pretreatment assessment
Before RT was initiated, we assessed the effects of the APP
cream and aloe vera gel on each patient's skin within the
planned field of irradiation. We found no difference
between the two products in either the score distributions
for the subject skin comfort assessment or the dermato-
logic assessment.
Assessment at follow-up
The analysis at follow-up was performed to detect longer
term differences between the two agents. Data for 29
patients (64%) were available at follow-up (7 ± 7 weeks,
median ± SD). Because both products were applied to the
skin of each patient, a paired t-test was used for this anal-
ysis. Patients gave the same or similar scores to the APP
cream and aloe vera gel for 11 of 15 (73%) variables: hurt,
burn, sting, wet, oily, greasy, feels good, feels funny, tick-
les, foreign body sensation. Of the remaining variables,
the score for "softness" tended to favor the use of the APP
cream (p = 0.083; Table 1). Because the scores for the two
products were identical before RT, the difference in scores
at follow-up reflects a difference in long-term efficacy. At
follow-up, the scores for the dermatologic assessment and
common toxicity criteria were the same for both products.
Assessments during RT (weeks 1–6)
There were four possible outcomes comparing APP cream
with aloe vera gel: (1) no difference; (2) cream ≥ gel, in
which the patients' APP cream score was never less than
their aloe vera gel score; (3) gel ≥ cream, in which the
patients' aloe vera gel score was never less than their APP
cream score; and (4) alternating, in which the product
with the higher score varied throughout the trial.
Most patients had the same scores on many assessment
variables. The gel ≥ cream outcome was found more often
than the cream ≥ gel outcome on the negative variables
(i.e., Dry, Rough, Itch, Dryness, Erythema, and Peely)
(Table 2). This finding suggests that although there was no
difference between the two agents in most patients; in
some patients the APP cream was better than the aloe vera
gel.
During RT, there was a difference in the CTC score favor-
ing the cream (P = 0.004). The cream CTC score in all
patients during RT was no larger than the gel CTC score.
On the other hand, in 9 patients (20%) the gel CTC score
was larger than cream CTC score at some point during RT.
Comparing the first and last assessments
Because both agents were administered in the same man-
ner and on the skin of the same patient, we removed the
individual effects by analyzing the difference of the two
scores (i.e., gel score – cream score) rather than the raw data.
We also compared the difference at the first assessment
with that at the last assessment. There were three possible
outcome groups: (1) first = last group, this group included
Table 1: Follow-up assessment of Subject Skin Comfort after 
APP cream and aloe vera gel treatment to prevent radiation 
dermatitis.
Variable Mean difference* SE p-value
Soft 0.2069 0.1151 0.083
Rough -0.069 0.0479 0.161
Itch -0.034 0.0345 0.326
Dry -0.034 0.0604 0.573
Smooth 0 0.0496 1.0
* The mean difference was calculated by cream score – gel score for 
each variable.Radiation Oncology 2007, 2:45 http://www.ro-journal.com/content/2/1/45
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those whose scores showed no change in gel – cream over
time; (2) first < last group, in which the gel – cream differ-
ence increased during the trial; and (3) first > last group, in
which the gel – cream difference decreased during the trial.
The frequencies of the outcome groups are given for statis-
tically significant variables in Table 3.
Treatment failure
Treatment failure according to the definitions of the study
occurred in 3 patients. Two patients had rhabdomyosar-
coma and one desmoids tumor with doses ranging from
45–50.4 Gy. The two patients with rhabdomyosarcoma
received concurrent chemotherapy. Failure occurred in
cream and gel treated sites simultaneously in two and in
the cream treated site prior to the gel treated site in one
patient.
Discussion
Prior to this trial and after radiation therapy was initiated,
the skin was usually treated daily with an aloe vera-based
gel. The patients or their caregivers would apply the gel
lightly and attempt to avoid any skin markings that facili-
tate localization of daily RT. When the prophylactic treat-
ment failed, as determined by the onset of moderate-to-
severe dryness, pruritus, erythema, and moist desquama-
tion, the next level of care was then instituted. This gener-
ally included a cleansing spray and moisture barrier that
contained zinc. If the patient experienced progressive
moist desquamation, peeling, or itching that was not
relieved with the cleansing spray or moisture barrier, then
a third level of care was indicated. This level included a
cleansing spray with the addition of alternating hydrocor-
tisone-containing cream (1%) and hydrocortisone (1%)/
Clioquinol (3%) cream.
The study demonstrated the superiority of a phospholi-
pid-based cream over an aloe vera based gel in the preven-
tion of radiation dermatitis in children receiving more
than 23.4 Gy. This conclusion is based on a statistical
analysis of subject skin comfort and dermatologic assess-
ment performed before, during, and after RT. The APP
cream was favored during treatment for the subject com-
fort variables of dry (0.002), softness (p = 0.057), feels
good (p = 0.002), and smoothness (p = 0.012). The APP
cream was also more efficacious during treatment for the
dermatologic variables of dryness (0.013), erythema (p =
0.002), and peely (p = 0.008). The similar subject skin
comfort assessment, dermatologic assessment, and com-
mon toxicity criteria scores observed when the first and
last treatments were compared, as well as those from pre-
treatment and follow-up assessments was surprising given
that 36 of 45 patients were treated with chemotherapy
before or during RT. Possible explanations would include
Table 3: Comparison of the First and Last Assessments of APP Cream and Aloe Vera Gel Effectiveness in Preventing Radiation 
Dermatitis in Pediatric Patients
 Assessment Variable First = Last* First < Last First > Last P-value**
Subject Skin Comfort Smooth 36 1 7 0.070
Dermatologic Dryness 29 12 3 0.035
Peely 37 7 0 0.016
Scaly 39 5 0 0.063
* The difference was calculated by cream score – gel score at first and last assessments for each variable.
**Two-sided exact P-values
Table 2: Comparison of APP cream and aloe vera gel effectiveness during RT.
Assessment Variable* No difference Cream > Gel Gel > Cream Cream > Gel, Gel > Cream P-value†
Subject Skin 
Comfort
Dry 25 2 15 2 0.002
Soft 27 11 3 3 0.057
Feels good 28 13 1 2 0.002
Rough 31 2 9 2 0.065
Smooth 32 10 1 1 0.012
Dermatologic Dryness 25 3 14 2 0.013
Erythema 33 0 10 1 0.002
Peely 35 0 8 1 0.008
Common Toxicity 
Criteria
CTC value 34 0 9 1 0.004
*The p-values of all variables listed, except CTC value, were less than 0.05.
†Two-sided exact p-value for equality of cream > gel frequency and gel > cream frequency.Radiation Oncology 2007, 2:45 http://www.ro-journal.com/content/2/1/45
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the relatively low dose of RT required for eligibility and
the rigor of the trial in applying skin care products on a
daily basis by trained personnel. This is further supported
by our results where failure occurred in only 3 patients,
two of whom received concurrent chemotherapy. One
might expect that a greater proportion of patients would
show a change over time, regardless of the agent applied,
if the total radiation dose was higher. For the design of
future trials, one might restrict the study cohort to include
patients who have the same diagnosis, RT site, and cancer
treatment regimen. Also, assessment of patients who
received a higher total dose of radiation may be informa-
tive.
Cytokine and cellular responses to radiation therapy in
the skin have been investigated to identify targets to miti-
gate the consequences of ionizing radiation therapy [18].
Commercial skin creams are primarily used to maintain
the outer surface of the stratum corneum. These creams
address only symptoms (e.g., dryness, flaking, or itching)
and not the primary cause of most skin maladies: compro-
mised bilayers and lamellae. The extracellular space
between the corneocytes is filled with polar lipids that
form the bilayers and lamellae (or polar membrane bilay-
ers).
Each lipid bilayer of the lamellae system is separated from
adjacent lipid bilayers by a water layer. These stacked
lamellae fill the space among the corneocytes. If the lipids
are compromised, then a wide range of skin disorders may
result, including dryness, flaking, cracking, and acceler-
ated aging. However, the organization of the lamellae is a
biochemical process; therefore, lamellae can repair them-
selves without intervention by living cells.
Desiccation of the lamellar system causes the bilayers to
align themselves into a crystalline-like structure that is
hard and brittle, and rehydration will re-establish the
organized bilayer system. Other factors degrade the skin
and are not helped by the current generation of skin prod-
ucts.
Two mechanisms of action are unique to the APP cream:
the repair of the lamellar system via the penetration of
APP and triglycerides into the bilayers of the stratum cor-
neum and the organization of water through the charged
nature of the molecules involved. This action repairs
defects (holes) in the strata that result from skin damage
and resultant loss of natural polar lipid components.
Two components of the cream formulation address lamel-
lar defects: APP and the triglycerides. Both molecules are
polar and water seeking; therefore, they are attracted to
the water layers of the stratum corneum, other layers of
the epidermis, and the underlying dermis, depending on
how severely the skin layers have been damaged. The driv-
ing forces for this penetrating action are the thermody-
namic forces involved: the amphiphilic interactions,
hydrogen bonding with water, electrostatic interactions,
and the hydrophobic interaction (the force that results in
water organization).
When APP molecules penetrate the stratum corneum and
arrive at a defective lipid bilayer, they insert themselves
alongside other polar lipids in the existing bilayer. Local
forces orient the APP molecules appropriately (i.e.,
hydrophilic ends to hydrophilic ends and hydrophobic
ends to hydrophobic ends). Like a zipper closing, the
repeated insertion of APP molecules fills the lamellar
defect, seals the gap, and thus re-establishes the water bar-
rier.
Conclusion
Reducing radiation-related toxicity is a central objective in
radiation oncology. The use of advanced methods of treat-
ment planning and delivery serve as examples of the effort
that is undertaken to diminish the toxicity of RT in the
adult and pediatric patient populations. As our ability to
reduce RT-related toxicity through technologic initiatives
plateaus, the importance of protecting normal tissues will
increase.
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